Amplia Therapeutics Limited

ASX (AUD): Amplia Therapeutics Limited (ATX)

Last Price

0.23

Today's Change

-0.01 (4.16%)

Day's Change

0.227 - 0.24

Trading Volume

3,801,547

Overview

Market Cap

111 Million

Shares Outstanding

486 Million

Avg Volume

6,827,321

Avg Price (50 Days)

0.19

Avg Price (200 Days)

0.11

PE Ratio

-11.50

EPS

-0.02

Earnings Announcement

30-May-2025

Previous Close

0.24

Open

0.24

Day's Range

0.227 - 0.24

Year Range

0.049 - 0.425

Trading Volume

3,801,547

Price Change Highlight

1 Day Change

-4.17%

5 Day Change

-4.17%

1 Month Change

-8.00%

3 Month Change

318.18%

6 Month Change

164.37%

Ytd Change

147.31%

1 Year Change

142.11%

3 Year Change

141.48%

5 Year Change

59.45%

10 Year Change

-84.14%

Max Change

-86.93%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Amplia Therapeutics Limited, a pharmaceutical company, focuses on development of focal adhesion kinase (FAK) inhibitors for oncology and chronic fibrosis in Australia. The company's product pipeline includes AMP945, an inhibitor of FAK, for pancreatic cancer and idiopathic pulmonary fibrosis, as well as other cancers and fibrotic diseases indications, that has completed Phase I clinical trial; and AMP886 for cancer and fibrotic disease indication. It has a collaboration agreement with the Garvan Institute of Media Research in Sydney. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.

Discussions
Be the first to like this. Showing 0 of 0 comments

{uid}

{comment}

Just now

Post a Comment